(NASDAQ: VTVT) Vtv Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.67%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34%.
Vtv Therapeutics's earnings in 2026 is -$26,974,000.On average, 7 Wall Street analysts forecast VTVT's earnings for 2026 to be -$11,738,764, with the lowest VTVT earnings forecast at -$18,488,830, and the highest VTVT earnings forecast at -$4,259,654. On average, 7 Wall Street analysts forecast VTVT's earnings for 2027 to be -$16,471,451, with the lowest VTVT earnings forecast at -$25,127,825, and the highest VTVT earnings forecast at -$13,151,166.
In 2028, VTVT is forecast to generate -$17,214,675 in earnings, with the lowest earnings forecast at -$27,250,759 and the highest earnings forecast at -$12,406,760.